Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4

References

• MaggardMAO’ConnellJBKoCYUpdated population-based review of carcinoid tumorsAnn Surg2004240111712215213627
   PubMed Web of Science ®Google Scholar
• YaoJCHassanMPhanAOne hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United StatesJ Clin Oncol200826183063307218565894
   PubMed Web of Science ®Google Scholar
• ShenCDasariAZhaoBIncidence and prevalence of neuroendocrine tumors in the United States 1973–2012. abstr 121 presented at NANETS 2016
   Google Scholar
• VinikAIWolteringEAWarnerRRNANETS consensus guidelines for the diagnosis of neuroendocrine tumorPancreas201039671373420664471
   PubMed Web of Science ®Google Scholar
• KunzPLReidy-LagunesDAnthonyLBConsensus guidelines for the management and treatment of neuroendocrine tumorsPancreas201342455757723591432
   PubMed Web of Science ®Google Scholar
• WongMHChanDLLeeASystematic review and meta-analysis on the role of chemotherapy in advanced and metastatic neuroendocrine tumor (NET)PLoS One2016116e015814027362760
   PubMedGoogle Scholar
• BajettaEProcopioGCatenaLLanreotide Autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a phase III studyCancer2006107102474248117054107
   PubMed Web of Science ®Google Scholar
• JansonETWestlinJEErikssonBAhlstromHNilssonSObergK[111In-DTPA-D-Phe1]octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatmentEur J Endocrinol199413165775817804439
   PubMed Web of Science ®Google Scholar
• CaplinMEPavelMCwiklaJBLanreotide in metastatic enteropancreatic neuroendocrine tumorsN Engl J Med2014371322423325014687
   PubMed Web of Science ®Google Scholar
• RinkeAMullerHHSchade-BrittingerCPlacebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study GroupJ Clin Oncol200927284656466319704057
   PubMed Web of Science ®Google Scholar
• Clewemar AntonodimitrakisPSundinAWassbergCGranbergDSkogseidBErikssonBStreptozocin and 5-fluorouracil for the treatment of pancreatic neuroendocrine tumors: efficacy, prog-nostic factors and toxicityNeuroendocrinology20161033–434535326279284
   PubMed Web of Science ®Google Scholar
• DilzLMDeneckeTSteffenIGStreptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumoursEur J Cancer201551101253126225935542
   PubMedGoogle Scholar
• KrugSBochMDanielHStreptozocin-based chemotherapy in patients with advanced neuroendocrine neoplasms-predictive and prognostic markers for treatment stratificationPLoS One20151012e014382226630134
   PubMedGoogle Scholar
• StrosbergJEl-HaddadGWolinEPhase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumorsN Engl J Med2017376212513528076709
   PubMed Web of Science ®Google Scholar
• CastellanoDBajettaEPanneerselvamAEverolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 studyOncologist2013181465323263288
   PubMed Web of Science ®Google Scholar
• FazioNGranbergDGrossmanAEverolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 studyChest2013143495596223187897
   PubMed Web of Science ®Google Scholar
• ItoTOkusakaTIkedaMEverolimus for advanced pancreatic neuroendocrine tumours: a subgroup analysis evaluating Japanese patients in the RADIANT-3 trialJpn J Clin Oncol2012421090391122859827
   PubMed Web of Science ®Google Scholar
• PavelMEHainsworthJDBaudinEEverolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 studyLancet201137898082005201222119496
   PubMed Web of Science ®Google Scholar
• YaoJCLombard-BohasCBaudinEDaily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trialJ Clin Oncol2010281697619933912
   PubMed Web of Science ®Google Scholar
• YaoJCShahMHItoTEverolimus for advanced pancreatic neuroendocrine tumorsN Engl J Med2011364651452321306238
   PubMed Web of Science ®Google Scholar
• YaoJCFazioNSinghSEverolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 studyLancet20163871002296897726703889
   PubMed Web of Science ®Google Scholar
• KlimstraDSModlinIRCoppolaDLloydRVSusterSThe pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systemsPancreas201039670771220664470
   PubMed Web of Science ®Google Scholar
• TherassePArbuckSGEisenhauerEANew guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of CanadaJ Natl Cancer Inst200092320521610655437
   PubMed Web of Science ®Google Scholar
• PavelMO’TooleDCostaFENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary siteNeuroendocrinology2016103217218526731013
   PubMed Web of Science ®Google Scholar
• ModlinIMPavelMKiddMGustafssonBIReview article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumoursAliment Pharmacol Ther201031216918819845567
   PubMed Web of Science ®Google Scholar
• KoumarianouAKaltsasGKulkeMHTemozolomide in advanced neuroendocrine neoplasms: pharmacological and clinical aspectsNeuroendocrinology2015101427428825924937
   PubMed Web of Science ®Google Scholar
• LamarcaAElliottEBarriusoJChemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: a lost cause?Cancer Treat Rev201644264126855376
   PubMed Web of Science ®Google Scholar
• BodeiLKwekkeboomDJKiddMModlinIMKrenningEPRadiolabeled somatostatin analogue therapy of gastroenteropancreatic cancerSemin Nucl Med201646322523827067503
   PubMed Web of Science ®Google Scholar
• BodeiLModlinIMLusterMMyeloid neoplasms after chemotherapy and PRRT: myth and realityEndocr Relat Cancer2016238C1C727353035
   PubMed Web of Science ®Google Scholar
• RaymondEDahanLRaoulJLSunitinib malate for the treatment of pancreatic neuroendocrine tumorsN Engl J Med2011364650151321306237
   PubMed Web of Science ®Google Scholar
• PhanATHalperinDMChanJAPazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 studyLancet Oncol201516669570325956795
   PubMed Web of Science ®Google Scholar
• BerardiRTorniaiMPuscedduSPrognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumorsCancer Med2017671493149928547856
   PubMedGoogle Scholar
• PanzutoFRinzivilloMFazioNReal-world study of everolimus in advanced progressive neuroendocrine tumorsOncologist201419996697425117065
   PubMed Web of Science ®Google Scholar
• KampKGumzBFeeldersRASafety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177) Lu-octreotateEndocr Relat Cancer201320682583124036133
   PubMedGoogle Scholar